Left Atrial Appendage Closure Versus DOAC Therapy in Atrial Fibrillation: A Phenotype-Centered Systematic Review and Meta-analysis of Randomized Trials
In brief
Atrial appendage closure cuts relevant bleeding 44% but more than doubles thromboembolism
Across five randomized trials involving 6,239 people with high-risk atrial fibrillation, left atrial appendage closure was linked to 44% fewer nonprocedural clinically relevant bleeding events than direct oral anticoagulants. Mortality and stroke outcomes did not differ, but closure was linked to more systemic thromboembolism, pericardial effusion, and serious adverse events, arguing for selective use rather than routine substitution.
- Journal
- American heart journal (Q1)
- Published
- 18 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Ayush Kumar, Muhammad Arham, Priya Kumar, Zahra Ali, Kartikeya Srivastava, Haris Bin Tahir, et al.
- PMID
- 43051386
- DOI
- 10.1016/j.ahj.2026.107658
Why clinicians should know about it
- Picked for Cardiology and Cardiovascular Medicine (paper of the day, 19 November 2026): Randomized-trial meta-analysis compares AF anticoagulation and appendage closure
Abstract
INTRODUCTION: Left atrial appendage closure (LAAC) has emerged as a selective alternative to long-term oral anticoagulation in appropriately selected patients with non-valvular high-risk atrial fibrillation (AF). However, individual contemporary RCTs remain underpowered to detect infrequent but clinically important outcomes. METHODOLOGY: This meta-analysis was prospectively registered in PROSPERO (CRD420261384938). A systematic literature search was conducted to identify RCTs comparing LAAC with direct oral anticoagulants (DOACs) therapy in patients with non-valvular high-risk AF. Statistical analyses were performed using R, with a two-sided significance threshold of p < 0.05. RESULTS: Five RCTs (n = 6,239; LAAC: 3,126; DOACs: 3,113) with 1:1 non-inferiority design were included. There were no significant differences between LAAC and DOACs for the composite endpoint, all-cause mortality or stroke. Systemic thromboembolism was significantly higher with LAAC (RR 2.53, 95% CI 1.04-6.19; p = 0.04; I² = 28.9%). LAAC was associated with significantly lower rates of minor bleeding (RR 0.48, 95% CI 0.40-0.58; p < 0.01; I² = 6.9%) and nonprocedural clinically relevant bleeding (RR 0.56, 95% CI 0.48-0.65; p < 0.01; I² = 0.0%). Pericardial effusion was significantly higher with LAAC (RR 2.35, 95% CI 1.15-4.83; p = 0.02; I² = 0.0%). Serious adverse events were modestly but significantly higher in the LAAC group (RR 1.08, 95% CI 1.02-1.14). CONCLUSION: In contemporary randomized trials, LAAC and DOAC-based therapy showed no significant differences in mortality or overall stroke outcomes but demonstrated divergent safety tradeoffs. LAAC was associated with less nonprocedural clinically relevant bleeding, while systemic thromboembolism, pericardial effusion, and serious adverse events occurred more frequently with device-based therapy. These findings support phenotype-specific selection of LAAC rather than routine substitution for evidence-based anticoagulation.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.